Sucampo Pharmaceuticals (NASDAQ:SCMP) will be posting its quarterly earnings results before the market opens on Tuesday, March 6th. Analysts expect Sucampo Pharmaceuticals to post earnings of $0.33 per share for the quarter.

Shares of Sucampo Pharmaceuticals (SCMP) opened at $18.00 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $18.75. The company has a market capitalization of $839.46, a price-to-earnings ratio of -5.37, a price-to-earnings-growth ratio of 5.06 and a beta of 1.38.

Several research firms have recently weighed in on SCMP. BidaskClub upgraded Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 12th. Leerink Swann restated a “market perform” rating and issued a $15.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Zacks Investment Research cut Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Nomura began coverage on Sucampo Pharmaceuticals in a research note on Monday, December 18th. They issued a “buy” rating and a $43.00 price target for the company. Finally, B. Riley boosted their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Sucampo Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $20.25.

In related news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now owns 52,023 shares in the company, valued at $858,379.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.13% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Sucampo Pharmaceuticals (SCMP) Set to Announce Quarterly Earnings on Tuesday” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with's FREE daily email newsletter.